$ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Maria L. Maccecchini
CEO
8
Employees
$2.15
Current Price
$47.81M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 3 | $142,778.91 | 76,344 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 3 | $142,778.91 | 76,344 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 4 | $1,641,758.91 | 790,144 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 4 | $1,641,758.91 | 790,144 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 20, 2026 | Hoffman Michael B Director | Purchase | 2,562 | $1.75 | $4,483.50 | View Details |
| May 20, 2026 | Hoffman Michael B Director | Purchase | 54,933 | $1.90 | $104,367.21 | View Details |
| May 20, 2026 | Hoffman Michael B Director | Purchase | 18,849 | $1.80 | $33,928.20 | View Details |
| Apr 2, 2026 | Hoffman Michael B Director | Purchase | 713,800 | $2.10 | $1,498,980.00 | View Details |
11 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.31
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.31
Actual-$0.39
Miss
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.31
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history